RESUMEN
OBJECTIVES: Investigation of diagnostic and prognostic relevance of BRCA1 immunohistochemistry (IHC) in endometrial carcinoma. METHODS: Ninty four specimens of endometrial carcinomas were evaluated. Full sections stained with hematoxylin & eosin were revaluated for assessment of tumor type, grade, myometrial, & lympho-vascular invasion (LVI). Tissue microarray blocks were constructed using the pencil tip method and immunostained with Anti-BRCA1 antibody. BRCA1 was correlated with clinicopathological parameters as well as disease free survival and overall survival. RESULTS: There was a statistically significant difference (P=0.001) between serous and endometroid carcinomas regarding BRCA1 expression where most cases of serous carcinoma showed negative expression. No statistically significant difference was found between BRCA1 positive and negative cases regarding disease free survival (DFS) or overall survival. Serous histotype, high grade, advanced stage, and omental deposits were the parameters significantly associated with decreased DFS. CONCLUSION: Results of this study can support inclusion of BRCA1 IHC in a panel to differentiate both endometroid and serous carcinomas. The current study found no prognostic relevance for BRCA1 in terms of overall survival and disease-free survival.
Asunto(s)
Proteína BRCA1 , Biomarcadores de Tumor , Neoplasias Endometriales , Inmunohistoquímica , Humanos , Femenino , Neoplasias Endometriales/patología , Neoplasias Endometriales/metabolismo , Proteína BRCA1/metabolismo , Persona de Mediana Edad , Pronóstico , Inmunohistoquímica/métodos , Biomarcadores de Tumor/metabolismo , Anciano , Tasa de Supervivencia , Estudios de Seguimiento , Adulto , Cistadenocarcinoma Seroso/patología , Cistadenocarcinoma Seroso/metabolismo , Carcinoma Endometrioide/patología , Carcinoma Endometrioide/metabolismoRESUMEN
Introduction Breast carcinoma is the most common malignancy in women worldwide. It is also one of the most frequent causes of brain metastasis (BM). Studies have identified BM as one of the worst prognostic signs. Methods We retrospectively analyzed data from 71 patients with BM from BC with the aim of clarifying the epidemiological criteria and management in our setting. We also aimed to identify predictors of survival and factors affecting the length of the BM-free interval in our group of patients. Results All the patients were female with a mean age at diagnosis of primary cancer of 41.6 years. The most common site of BM was the parietal lobe. The BM-free interval was longer with N1 disease (in comparison to N2 and 3) and in luminal B breast cancer subtype. Survival was shorter in older patients, those with hormone receptor negative and/or HER2-neu positive disease, synchronous BM, primary tumour not removed, soft tissue/non-regional nodes concomitant metastasis, and those who did not receive palliative chemotherapy. Survival tended to be longer in patients with temporal lobe metastasis, but this result was not statistically significant. Conclusion BM is a bad prognostic sign. Large scale prospective studies are needed to further delineate its nature. (AU)
Introducción El carcinoma de mama es la neoplasia maligna más común en las mujeres del mundo. Además, es una de las causas más comunes de metástasis cerebral (MC). Los estudios detectan MC como uno de los peores signos pronósticos. Métodos Analizamos retrospectivamente los datos de 71 pacientes con MC de origen mamario con el objetivo de clarificar los criterios epidemiológicos y el esquema de manejo en nuestra localidad de esta enfermedad, además de detectar predictores de supervivencia y factores que afectan la longitud del intervalo libre de MC en nuestro grupo de pacientes. Resultados Todos los pacientes fueron mujeres con una edad media de diagnóstico de cáncer primario de 41,6 años. El sitio más común de MC fue el lóbulo parietal. El intervalo libre de propagación cerebral fue más largo con la enfermedad N1 (en comparación con N2 y 3) y en el subtipo de cáncer de mama luminal B. La supervivencia fue menor en pacientes mayores, aquellos con receptores hormonales negativos y/o enfermedad HER2-neu positiva, MC sincrónica, tumor primario no extirpado, metástasis concomitantes de tejido blando nodos no regionales y aquellos que no recibieron quimioterapia paliativa. Además, aquellos con metástasis del lóbulo temporal tienden a tener una mejor supervivencia, aunque no alcanzaron significación estadística. Conclusión La MC es un mal signo pronóstico. Se necesitan estudios prospectivos a gran escala para delinear aún más su naturaleza. (AU)